Is Teva Among Finalists In Bidding For Germany's Ratiopharm? (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Ratiopharm would bring market share, geographic diversification, and an attractive OTC business - if the price is right.
You may also be interested in...
Teva Wins Ratiopharm For $5 Billion And Gains A Key Foothold In Europe
Teva has emerged as the winner in a months-long bidding war for ratiopharm, Germany's second-largest generics manufacturer after Novartis's Sandoz unit
Teva Wins Ratiopharm For $5 Billion And Gains A Key Foothold In Europe
Teva has emerged as the winner in a months-long bidding war for ratiopharm, Germany's second-largest generics manufacturer after Novartis's Sandoz unit
Teva Wins Ratiopharm For $5 Billion, And Gains A Key Foothold In Europe
The acquisition makes Teva the leading generics company in Europe, which is a key to its ambitious plans for global growth.